Research Atlas · source screening

Mifamurtide

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Scope: Single-source, name-in-title discovery sample. Not a systematic review, worldwide source coverage, clinical appraisal, efficacy or safety conclusion, or complete WPF profile. This source index is separate from the Public Peptide Directory and from human observations.

Title-search results: 35
Shown with stable PMIDs: 25
Search recorded: 2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Mifamurtide"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

Does mifamurtide affect the elimination of high-dose methotrexate in children with osteosarcoma?
Cancer Chemother Pharmacol · 2026 Apr 18 · PMID 41999402 · DOI 10.1007/s00280-026-04883-z
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.
J Clin Oncol · 2026 Apr 10 · PMID 41534017 · DOI 10.1200/JCO-25-02154
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.
J Clin Oncol · 2026 Apr 10 · PMID 41534000 · DOI 10.1200/JCO-25-02624
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.
J Clin Oncol · 2025 Oct · PMID 40825172 · DOI 10.1200/JCO-25-00210
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
Med Oncol · 2025 Sep 17 · PMID 40960554 · DOI 10.1007/s12032-025-03038-z
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.
Clin Cancer Res · 2025 Sep 15 · PMID 40711479 · DOI 10.1158/1078-0432.CCR-25-0649
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.
AAPS PharmSciTech · 2024 Nov 26 · PMID 39592553 · DOI 10.1208/s12249-024-02992-7
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma.
Cancers (Basel) · 2023 Sep 27 · PMID 37835437 · DOI 10.3390/cancers15194744
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
BMC Cancer · 2022 Jun 8 · PMID 35672690 · DOI 10.1186/s12885-022-09697-9
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.
Invest New Drugs · 2022 Jun · PMID 35312944 · DOI 10.1007/s10637-022-01225-7
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis.
J Bone Oncol · 2021 Jun · PMID 33948428 · DOI 10.1016/j.jbo.2021.100362
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells.
Oncotarget · 2020 Feb 18 · PMID 32133045 · DOI 10.18632/oncotarget.27479
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Type 4 hypersensitivity development in a case due to mifamurtide.
Turk J Pediatr · 2020 · PMID 32779428 · DOI 10.24953/turkjped.2020.04.025
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma.
BMJ Open · 2019 May 19 · PMID 31110092 · DOI 10.1136/bmjopen-2018-025877
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma.
J Pediatr Hematol Oncol · 2018 Aug · PMID 29889801 · DOI 10.1097/MPH.0000000000001236
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
JBI Database System Rev Implement Rep · 2017 Aug · PMID 28800058 · DOI 10.11124/JBISRIR-2016-003105
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.
Curr Cancer Drug Targets · 2017 · PMID 27993113 · DOI 10.2174/1568009616666161215163426
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.
Tumour Biol · 2015 Sep · PMID 25835978 · DOI 10.1007/s13277-015-3405-3
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.
Expert Rev Pharmacoecon Outcomes Res · 2015 Apr · PMID 25354299 · DOI 10.1586/14737167.2015.972378
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain.
Value Health · 2014 Nov · PMID 27201662 · DOI 10.1016/j.jval.2014.08.1662
Source metadata only · evidence grade unassigned · scientific conclusions pending review
The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis.
Tumour Biol · 2014 Sep · PMID 24874050 · DOI 10.1007/s13277-014-2139-y
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Br J Clin Pharmacol · 2014 Jun · PMID 24134216 · DOI 10.1111/bcp.12261
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
Br J Clin Pharmacol · 2014 Jun · PMID 24134181 · DOI 10.1111/bcp.12260
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Pediatr Blood Cancer · 2014 Feb · PMID 23997016 · DOI 10.1002/pbc.24686
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.
Value Health · 2013 Dec · PMID 24326165 · DOI 10.1016/j.jval.2013.08.2294
Source metadata only · evidence grade unassigned · scientific conclusions pending review

Loading research intelligence

Preparing the structured Flagship evidence library.